Search clinical trials for: Advanced squamous NSCLC

Total 28380 results

BeiGene

Not yet recruiting

A Phase 1 Study of BGB-B2033, Alone or in Combination With Tislelizumab, in Participants With Advanced or Metastatic Solid Tumors

Metastatic Solid Tumor | Advanced Hepatocellular Carcinoma | Metastatic Hepatocellular Carcinoma | Alpha-fetoprotein (AFP)-Producing Gastric Cancer | Extragonadal Yolk Sac Tumors | Glypican-3 (GPC3)-Positive Squamous Non-small Cell Lung Cancer
Novartis Pharmaceuticals

Not yet recruiting

A Phase I Study of [177Lu]Lu-EVS459 in Patients With Ovarian and Lung Cancers

Ovarian Cancer | Lung Cancer
AstraZeneca
Daiichi Sankyo

Recruiting

Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations (TROPION-Lung10)

Non-Small Cell Lung Cancer

Spain, Italy, Japan, Brazil, Taiwan, Korea, Republic of, Australia, Austria, Canada, Poland, United States, Belgium, United Kingdom, Turkey, Hungary, Germany, India
Shanghai Shengdi Pharmaceutical Co., Ltd

Not yet recruiting

A Phase II/III Study of Adebrelimab in Combination With SHR-8068 and Chemotherapy in Advanced or Metastatic NSCLC Patients

Non-squamous Non-small Cell Lung Cancer

China
Eikon Therapeutics

Recruiting

A Phase 2 Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Patients With Stage 4 Non-Small Cell Lung Cancer

NSCLC

United States
Xencor, Inc.

Recruiting

Study of Vudalimab or Pembrolizumab in Combination With Chemotherapy as First-line Treatment in Patients With Advanced NSCLC

Nonsquamous Non-small Cell Lung Cancer

United States
AbbVie

Recruiting

A Study to Assess the Safety, Pharmacokinetics, and Efficacy of Intravenous (IV) ABBV-303, as Monotherapy and in Combination With IV Infused Budigalimab (ABBV-181), in Adults With Advanced Solid Tumors

Solid Tumors

United States, Israel
Fusion Pharmaceuticals Inc.
AstraZeneca

Not yet recruiting

A Phase 1, Dose-escalation Study of [225Ac]-FPI-2068 in Adult Patients With Advanced Solid Tumours

Advanced Solid Tumor | Non-small Cell Lung Cancer | Head and Neck Squamous Cell Carcinoma | Pancreatic Ductal Adenocarcinoma | Metastatic Colorectal Carcinoma

United States, Canada
Hubei Cancer Hospital

Recruiting

Primary Tumor Radiotherapy Omitting CTV for Patients With Advanced NSCLC Responded to Immunotherapy and Chemotherapy

Radiotherapy | Immunotherapy | Advanced Non-Small Cell Squamous Lung Cancer

China
Peking University First Hospital
Merck Sharp & Dohme LLC

Not yet recruiting

Efficacy and Safety of Nab-paclitaxel-Lenvatinib-Pembrolizumab as Second-line Treatment in Advanced NSCLC Patients

Advanced Non-squamous Non-small-cell Lung Cancer | Metastatic Non-squamous Non Small Cell Lung Cancer | Recurrent Non-Squamous Non-Small Cell Lung Cancer

China
Seagen Inc.

Recruiting

A Study of SGN-EGFRd2 in Advanced Solid Tumors

Carcinoma, Non-Small-Cell Lung | Colorectal Neoplasms | Squamous Cell Carcinoma of the Head and Neck | Pancreatic Ductal Adenocarcinoma

United States
DualityBio Inc.

Recruiting

A Study of DB-1311 in Advanced/Metastatic Solid Tumors

Advanced Solid Tumors

United States, Australia
Hummingbird Bioscience
Merck KGaA, Darmstadt, Germany

Recruiting

Study of an Anti-HER3 Antibody, HMBD-001, With Docetaxel +/- Cetuximab in Advanced Squamous Non-small Cell Lung Cancers

Advanced or Metastatic Squamous Non-Small Cell Lung Cancer

Australia, Singapore
Sichuan University
Shanxi Provincial Cancer Hospital; Mianyang Central Hospital; Chengdu First people... and other collaborators

Not yet recruiting

Trilaciclib Prior to Chemotherapy Plus Tislelizumab as 1L Treatment for Advanced Squamous Non-Small-Cell Lung Cancer

Advanced Squamous Non-Small-Cell Lung Cancer
Arcus Biosciences, Inc.

Recruiting

Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers (ARC-25)

Cervical Cancer | Gastric Cancer | Esophageal Cancer | Ovarian Cancer | Bladder Cancer | Advanced Cancer | Non-Small Cell Lung Cancer (NSCLC) | Advanced Malignancies | Renal Cell Carcinoma (RCC) | Triple Negative Breast Cancer (TNBC) | Head and Neck Squamous Cell Carcinoma (HNSCC) | Gastroesophageal-junction...

United States, Australia
MedSIR
Daiichi Sankyo

Recruiting

HER3-DXd in Breast Cancer and NSCLC Brain Metastases and Solid Tumor Leptomeningeal Disease (TUXEDO-3)

Metastatic Breast Cancer | Solid Tumor, Adult | Advanced Non-Small Cell Squamous Lung Cancer

Spain, Austria
Innovent Biologics (Suzhou) Co. Ltd.

Not yet recruiting

The Study of Tusamitamab Ravtansine (IBI126) Combined With Sintilimab and Tusamitamab Ravtansine (IBI126) Combined With Sintilimab Plus Platinum-based Chemotherapy and Pemetrexed in Subjects With CEACAM5 Positive Expression Advanced/Metastatic Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC)

Non-squamous Non-small-cell Lung Cancer

China
DualityBio Inc.

Recruiting

A Study of DB-1310 in Advanced/Metastatic Solid Tumors

Advanced Solid Tumor

United States, China
Jiangsu Cancer Institute & Hospital

Not yet recruiting

Study of Polymeric Micellar Paclitaxel, Platinum Combined With Sindilizumab Injection for Advanced Non-squamous NSCLC

Non-squamous NSCLC

China
Mythic Therapeutics

Recruiting

Clinical Study of Antibody-Drug Conjugate MYTX-011 in Subjects With Non-Small Cell Lung Cancer

Non-Small Cell Lung Cancer | NSCLC | Advanced Non-Small Cell Lung Cancer | NSCLC Stage IV | NSCLC Stage IIIB | Advanced Non-Small Cell Squamous Lung Cancer | Advanced Non-Small Cell Non-Squamous Lung Cancer

United States, Australia, Korea, Republic of, United Kingdom
ETOP IBCSG Partners Foundation
Janssen Pharmaceuticals

Recruiting

AMAZE-lung: Amivantamab, Lazertinib and Bevacizumab in Patients With EGFR-mutant Advanced Non-small Cell Lung Cancer With Progression on Previous Third-generation EGFR-TKI (AMAZE-lung)

Non Small Cell Lung Cancer

Spain, France, Switzerland, United Kingdom, Singapore, Italy, Netherlands
Novartis Pharmaceuticals

Recruiting

A Study of Safety and Efficacy of KFA115 Alone and in Combination With Pembrolizumab in Patients With Select Advanced Cancers

Carcinoma, Renal Cell | Carcinoma, Non-Small-Cell Lung | Nasopharyngeal Carcinoma | Carcinoma, Ovarian Epithelial | Mesothelioma | Squamous Cell Carcinoma of Head and Neck | Triple Negative Breast Neoplasms | Anal Cancer | Cutaneous Melanoma | Esophagogastric Cancer | Carcinoma, Thymic | High Microsatellite...

Italy, Spain, Singapore, Germany, Taiwan, Japan, Canada, Hong Kong, United States
Bayer

Recruiting

A First-in-human Study to Learn How Safe the Study Drug BAY3375968, an Anti-CCR8 Antibody, is, When Given Alone or in Combination With Pembrolizumab, How it Affects the Body, How it Moves Into, Through, and Out of the Body, and to Find the Best Dose in Participants With Advanced Solid Tumors

Advanced Solid Tumors

United States, Canada, Belgium, Singapore, China, Spain, United Kingdom
AP Biosciences Inc.

Not yet recruiting

A Study to Investigate the Safety, Pharmacokinetics, and Clinical Activity of AP203 in Patients With Locally Advanced or Metastatic Solid Tumors, and Expansion to Selected Malignancies (APT-CUBE)

Esophageal Squamous Cell Carcinoma (ESCC) | Locally Advanced or Metastatic Solid Tumors | Non Small Cell Lung Cancer (NSCLC) | Head and Neck Squamous Cell Carcinoma (HNSCC)
Novartis Pharmaceuticals

Recruiting

A Study to Investigate the Safety and Tolerability of Intravenous QEQ278 in Patients With Advanced Solid Tumors

Carcinoma, Renal Cell | Carcinoma, Non-Small-Cell Lung | Squamous Cell Carcinoma of Head and Neck | Esophageal Squamous Cell Carcinoma

Japan, France, Italy, Spain, Belgium, Germany, Taiwan, United States, Singapore
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Recruiting

A Study of TQB2450 Injection Plus Chemotherapy Followed by TQB2450 Plus Anlotinib Versus Tislelizumab Plus Chemotherapy Followed by Tislelizumab in the Treatment of First-line Non-squamous Non-small Cell Lung Cancer(NSCLC).

Advanced Non-squamous Non-small Cell Lung Cancer

China
Sung Yong Lee
Yuhan Corporation

Recruiting

A Study of Lazertinib as Consolidation Therapy in Patients With Locally Advanced, Unresectable, EGFR-Mutant Non-Small Cell Lung Cancer (Stage III) Following Chemoradiation Therapy (PLATINUM)

Non-small Cell Lung Cancer Stage III | Non-squamous Non-small-cell Lung Cancer | EGFR Positive Non-small Cell Lung Cancer

Korea, Republic of
GlaxoSmithKline

Recruiting

First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid Tumors

Neoplasms

United States, Australia, Spain, Canada, France, Korea, Republic of, United Kingdom, Japan, China
Aulos Bioscience, Inc.

Recruiting

Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer

Metastatic Cancer | Advanced Solid Tumor

Australia, United States
Black Diamond Therapeutics, Inc.

Recruiting

Phase 1/2 Study of BDTX-1535 in Patients With Glioblastoma or Non-Small Cell Lung Cancer With EGFR Mutations

Non-Small Cell Lung Cancer | NSCLC | Metastatic Lung Cancer | Metastatic Lung Non-Small Cell Carcinoma | EGF-R Positive Non-Small Cell Lung Cancer | Advanced Lung Carcinoma | EGFR-TKI Resistant Mutation | Advanced Non-Small Cell Squamous Lung Cancer | Epidermal Growth Factor Receptor C797S | Epidermal...

United States
Seagen Inc.

Recruiting

A Study of SGN-PDL1V in Advanced Solid Tumors

Melanoma | Carcinoma, Non-Small-Cell Lung | Gastric Cancer | Ovarian Neoplasms | Squamous Cell Carcinoma of the Head and Neck | Triple Negative Breast Neoplasms | Esophageal Squamous Cell Carcinoma

United States, Spain, Italy, Canada, United Kingdom, France, Belgium, Germany, Netherlands
Sun Yat-sen University

Recruiting

Tislelizumab Plus Chemotherapy as First-Line Treatment for Advanced Squamous NSCLC With Brain Metastases

Brain Metastases | Non-Small Cell Squamous Lung Cancer

China
Maia Biotechnology

Recruiting

THIO Sequenced With Cemiplimab in Advanced NSCLC

Carcinoma, Non-Small-Cell Lung

Poland, Australia, Bulgaria, Hungary
Nurix Therapeutics, Inc.

Recruiting

A Study of NX-1607 in Adults With Advanced Malignancies

Cervical Cancer | Gastric Cancer | Head and Neck Squamous Cell Carcinoma | Non-small Cell Lung Cancer (NSCLC) | Metastatic Urothelial Carcinoma | Ovarian Cancer, Epithelial | Metastatic Castration-resistant Prostate Cancer (mCRPC) | Triple Negative Breast Cancer (TNBC) | Malignant Pleural Mesothelioma... and other conditions

United States, United Kingdom
Medicenna Therapeutics, Inc.
Merck Sharp & Dohme LLC

Recruiting

A Beta-only IL-2 ImmunoTherapY Study (ABILITY-1)

Clear Cell Renal Cell Carcinoma | Cervical Cancer | Gastric Cancer | Esophageal Cancer | Ovarian Cancer | Fallopian Tube Cancer | Solid Tumor | Squamous Cell Carcinoma of Head and Neck | Bladder Cancer | Skin Cancer | Triple Negative Breast Cancer | Advanced Solid Tumor | Primary Peritoneal Cancer | Endometrial Carcinoma and other conditions

United States, Australia, Korea, Republic of, Canada
Takeda

Recruiting

A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tumors

Kidney Cancer | Breast Cancer | Nasopharyngeal Cancer | Gastric Cancer | Pancreatic Cancer | Esophageal Cancer | Mesothelioma | Hepatocellular Cancer | Squamous Cell Cancer of Head and Neck (SCCHN) | Non-small Cell Lung Cancer (NSCLC), Non-squamous

United States
Boehringer Ingelheim

Recruiting

A Study to Test How BI 765063 and BI 770371 Are Taken up in Tumours of People With Different Types of Advanced Cancer Who Are Also Taking Ezabenlimab

Melanoma | Non-small Cell Lung Cancer (NSCLC) | Carcinoma, Squamous Cell of Head and Neck (HNSCC)

Netherlands
Cancer Research UK
Hummingbird Bioscience

Recruiting

HMBD-001 in Advanced HER3 Positive Solid Tumours

Melanoma | Cervical Cancer | Gastric Cancer | Pancreatic Cancer | Ovarian Cancer | Hepatocellular Carcinoma (HCC) | Bladder Cancer | Triple Negative Breast Cancer | Endometrial Cancer | Castration-resistant Prostate Cancer | Non-small Cell Lung Cancer (NSCLC) | Oesophageal Cancer | RAS Wild Type Colorectal Cancer | Squamous Cell Cancer of the Head and Neck

United Kingdom
AstraZeneca
Daiichi Sankyo

Recruiting

A Study to Investigate the Efficacy and Safety of Trastuzumab Deruxtecan as the First Treatment Option for Unresectable, Locally Advanced/Metastatic Non-Small Cell Lung Cancer With HER2 Mutations

Locally Advanced or Metastatic Non-Small Cell Lung Cancer

China, Korea, Republic of, Germany, Italy, Poland, Belgium, Mexico, Turkey, Spain, France, United States, Canada, Taiwan, Brazil, Austria, Hong Kong, India, Japan, Netherlands, Denmark
Georgetown University
Genentech, Inc.

Recruiting

Tiragolumab With Atezolizumab Plus Bevacizumab in Previously-Treated Advanced Non-squamous NSCLC

Non-squamous Non-small-cell Lung Cancer

United States
Bristol-Myers Squibb

Recruiting

A Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors

Melanoma | Carcinoma, Renal Cell | Cervical Cancer | Pancreatic Adenocarcinoma | Ovarian Neoplasms | Squamous Cell Carcinoma of Head and Neck | Triple Negative Breast Neoplasms | Urothelial Carcinoma | Microsatellite Stable Colorectal Cancer | Non-Small-Cell Lung Cancer | Gastric/Gastroesophageal Junction...

United States, Australia, Italy, Germany, Spain, Canada, Israel, Japan
Merus N.V.

Recruiting

A Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR and Anti-c-MET Bispecific Antibody, in Patients With Advanced NSCLC and Other Solid Tumors

Gastric Cancer | Head and Neck Squamous Cell Carcinoma | Esophageal Squamous Cell Carcinoma | Non-Small Cell Lung Cancer Metastatic

United States, Spain, France, Italy, Netherlands, Belgium, Korea, Republic of, Germany, Singapore
The First Affiliated Hospital with Nanjing Medical...

Recruiting

Sintilimab, Anlotinib Hydrochloride and Platinum-Containing Dual-Agent Chemotherapy in NSCLC

Metastatic NSCLC | Recurrent NSCLC | Advanced Non-Small Cell Squamous Lung Cancer

China
Takeda

Recruiting

A Study of TAK-186 (Also Known as MVC-101) in Adults With Advanced or Metastatic Cancer

Colorectal Cancer | Non-small Cell Lung Cancer (NSCLC) | Squamous Cell Cancer of Head and Neck (SCCHN)

Korea, Republic of, United States, Australia
IDEAYA Biosciences

Recruiting

Study of IDE397 in Participants With Solid Tumors Harboring MTAP Deletion

Solid Tumor

United States, Taiwan, Korea, Republic of, France, Spain, Australia, Germany
Calico Life Sciences LLC
AbbVie

Recruiting

A Phase 1 Study With ABBV-CLS-484 in Subjects With Locally Advanced or Metastatic Tumors

Advanced Solid Tumor Cancer

United States, Korea, Republic of, Israel, Spain, Japan, France
AstraZeneca
Daiichi Sankyo

Recruiting

Phase Ib Study of the Safety of T-DXd and Immunotherapy Agents With and Without Chemotherapy in Advanced or Metastatic HER2+, Non-squamous NSCLC (DL03)

Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Korea, Republic of, Italy, Poland, Malaysia, Taiwan, Thailand, United States, France, Netherlands, Philippines, Canada, Singapore, Spain, Turkey, Australia, Belgium, Israel
Junling Li

Recruiting

Camrelizumab Plus Apatinib for Advanced Non-Squamous NSCLC Previously Treated With First-Line Immunotherapy

Advanced Non Squamous NSCLC

China
Sichuan Baili Pharmaceutical Co., Ltd.
SystImmune Inc.

Recruiting

A Study of SI-B001, an EGFR/HER3 Bispecific Antibody, in Locally Advanced or Metastatic Epithelial Tumors

Locally Advanced or Metastatic Epithelial Tumor

China
University of Texas Southwestern Medical Center

Recruiting

Phase 2 Trial of Afatinib Plus Prednisone for Advanced Squamous NSCLC

Advanced Squamous Non Small Cell Lung Cancer

United States

Search clinical trials for: Advanced squamous NSCLC

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Moldova

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations